next announcement and likely content, page-118

Roy , seriously read the AGM presentation or the biotech DD link I put up or even read isis annual report.

AGM presentation

“Genzyme (Isis) Mipomersen – successful Phase III in high risk cholesterol patients”

Successful!!

Licence to market in USA is delayed due to FDA delays, but will be on market in europe by March.

Due to Mipomersen – successful Phase III in high risk cholesterol patients, The initial regulatory filings in the US and EU will result in approval, likely by mid-2012 and perhaps earlier based on SNY's projection that Kynamro (Mipomersen) will be launched by March 2012.

http://www.biotechduediligence.com/mipomersen-long-term-safety-and-efficacy.html

Your welcome, Roy!


This time goodbye for real so please don’t address your posts to me any longer!


Good Luck!